Oryzon Genomics SA is getting $21 million in up-front and near-term milestones and could earn more than $500 million in total from a partnering deal with Roche AG on its lysine-specific demethylase-1 (LSD1) inhibitor program. The agreement is a major validation for Barcelona, Spain-based Oryzon – and for an epigenetic target with a growing body of evidence linking it to cancer and several other broad indication areas.